Search Results | Blood | American Society of Hematology

1-20 of 122

2 3 4 5

Sort by

Sort Order Select

Journal Articles

N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma

Shiqiao Ye, Yu Chen, Bo Hu, Huayu Huang, Yuxiao Sun, James P Stewart, Sarah K Johnson, Bart Barlogie, Maurizio Zangari, Guido Tricot, Faith E Davies, Gareth J Morgan, Brian A Walker, Fenghuang Zhan, Frits van Rhee, John D Shaughnessy, Jr., Ya-Wei Qiang

Blood (2021) 138 (Supplement 1): 1572.

DOI: https://doi.org/10.1182/blood-2021-148624

Published: 2021

Journal Articles

Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome

Meera Mohan, Zimu Gong, Samantha Kendrick, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, Guido Tricot, Fenghuang Zhan, Frits van Rhee, Jeffery R. Sawyer, Erming Tian, Maurizio Zangari

Blood (2021) 138 (Supplement 1): 1627.

DOI: https://doi.org/10.1182/blood-2021-145822

Published: 2021

Journal Articles

Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance

Naveen K Yarlagadda, Meera Mohan, Shebli Atrash, Sravani Gundarlapalli, Shadiqul Hoque, Sunil Kakadia, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, Guido Tricot, Erming Tian, Jeffery R. Sawyer, Fenghuang Zhan, Frits van Rhee, Maurizio Zangari

Blood (2021) 138 (Supplement 1): 2713.

DOI: https://doi.org/10.1182/blood-2021-148228

Published: 2021

Journal Articles

Deep Profiling of the Immune Microenvironment throughout Myeloma Disease Stages

Megan Darrington, Frits van Rhee, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Fenghuang Zhan, Brian A Walker, Gareth J. Morgan, Sarah K Johnson

Blood (2021) 138 (Supplement 1): 727.

DOI: https://doi.org/10.1182/blood-2021-148590

Published: 2021

Journal Articles

NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma

Yan Cheng, Fumou Sun, Huojun Cao, Dongzheng Gai, Bailu Peng, Hongwei Xu, Frits van Rhee, Siegfried Janz, Guido Tricot, John D Shaughnessy, Jr., Fenghuang Zhan

Blood (2021) 138 (Supplement 1): 2671.

DOI: https://doi.org/10.1182/blood-2021-148659

Published: 2021

Journal Articles

Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma

Fumou Sun, Yan Cheng, Bailu Peng, Hongwei Xu, Frits van Rhee, Siegfried Janz, Guido Tricot, John D Shaughnessy, Jr., Fenghuang Zhan

Blood (2021) 138 (Supplement 1): 2802.

DOI: https://doi.org/10.1182/blood-2021-148543

Published: 2021

Journal Articles

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma

Xuelian Tan, Timothy Cody Ashby, PhD, Yuqi Zhu, Can Li, MD, Xuxing Shen, MBBS, Qierra Brockman, BA, Dongzheng Gai, MD, Sarah K Johnson, PhD, Donghoon Yong, Carolina D. Schinke, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, John Shaughnessy, Jr., PhD, Dingming Huang, PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2020) 136 (Supplement 1): 2.

DOI: https://doi.org/10.1182/blood-2020-140372

Published: 2020

Journal Articles

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

Dongzheng Gai, MD, Stewart JP, Xuxing Shen, Jin-Ran Chen, PhD, Can Li, MD, Bailu Peng, PhD, Ya-Wei Qiang, MD PhD, Shmuel Yaccoby, PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Guido J. Tricot, MD PhD, Lijuan Chen, MDPhD, John Shaughnessy, Jr., PhD, Fenghuang Zhan, MD PhD

Blood (2020) 136 (Supplement 1): 21.

DOI: https://doi.org/10.1182/blood-2020-140568

Published: 2020

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

DOI: https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Can Li, MD, Reinaldo Franqui-Machin, Jiliang Xia, PhD, Gregory S. Thomas, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 854.

DOI: https://doi.org/10.1182/blood-2019-123818

Published: 2019

Journal Articles

1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma

Chenxing Du, An Gang, MD, Yan Xu, Xuehan Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Li Zengjun, Chengwen Li, Shuhua Yi, MD, Mu Hao, Dehui Zou, MD, Fenghuang Zhan, MD PhD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4343.

DOI: https://doi.org/10.1182/blood-2019-129739

Published: 2019

Journal Articles

Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma

Can Li, MD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 5538.

DOI: https://doi.org/10.1182/blood-2019-121933

Published: 2019

Journal Articles

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

Yuqi Zhu, Ye Yang, PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3102.

DOI: https://doi.org/10.1182/blood-2019-123815

Published: 2019

Journal Articles

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

Can Li, MD, Xuelian Tan, Qierra Brockman, BA, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Marta Chesi, PhD, P. Leif Bergsagel, MD, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3059.

DOI: https://doi.org/10.1182/blood-2019-123473

Published: 2019

Journal Articles

High Expression of NEK2 Mediated By p53 Contributes to Progression and Relapse of Multiple Myeloma

Wen Zhou, PhD, Fenghuang Zhan, MD PhD

Blood (2018) 132 (Supplement 1): 192.

DOI: https://doi.org/10.1182/blood-2018-192

Published: 2018

Journal Articles

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Sarah L Mott, Jillna Claus, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Guido J. Tricot, MD PhD

Blood (2018) 132 (Supplement 1): 2152.

DOI: https://doi.org/10.1182/blood-2018-99-113890

Published: 2018

Journal Articles

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Gabrielle Berns, Jillna Claus, Sarah L Mott, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MD FRCPath, MRCP

Blood (2018) 132 (Supplement 1): 2153.

DOI: https://doi.org/10.1182/blood-2018-99-118443

Published: 2018

Journal Articles

Single-Cell Analysis Reveals Sequential Genetic Events from Hematopoietic Stem Cell Differentiation Hierarchy in Multiple Myeloma Patients with FGFR3/IGH Translocation

Wen Zhou, PhD, Fenghuang Zhan, MD PhD

Blood (2018) 132 (Supplement 1): 5598.

DOI: https://doi.org/10.1182/blood-2018-99-115606

Published: 2018

Journal Articles

Potential Metabolite Markers of Multiple Myeloma

Jiliang Xia, PhD, Jingyu Zhang, Xuan Wu, ShiLian Chen, Jingchao Lin, Mingming Su, Jiaojiao Guo, Yongjun Guan, Minghua Wu, Lugui Qiu, MD, Fenghuang Zhan, MD, Wen Zhou, PhD

Blood (2018) 132 (Supplement 1): 3163.

DOI: https://doi.org/10.1182/blood-2018-99-115934

Published: 2018

Journal Articles

The Nek2 Genetic Knockout Mouse Model Provides Novel Treatment Strategies in Myeloma and Lymphoma

Li Can, MD, Kalyan Nadiminti, Yuqi Zhu, Yogesh Jethava, MBBS, MD FRCPath, MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2018) 132 (Supplement 1): 5612.

DOI: https://doi.org/10.1182/blood-2018-99-115099

Published: 2018

2 3 4 5

NARROW

N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma

Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome

Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance

Deep Profiling of the Immune Microenvironment throughout Myeloma Disease Stages

NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma

Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma

Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

High Expression of NEK2 Mediated By p53 Contributes to Progression and Relapse of Multiple Myeloma

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

Single-Cell Analysis Reveals Sequential Genetic Events from Hematopoietic Stem Cell Differentiation Hierarchy in Multiple Myeloma Patients with FGFR3/IGH Translocation

Potential Metabolite Markers of Multiple Myeloma

The Nek2 Genetic Knockout Mouse Model Provides Novel Treatment Strategies in Myeloma and Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only